HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Trimipramine

HCID 5584
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
3564-66-7
Standard SMILES
CC(CN(C)C)CN1c2ccccc2CCc2ccccc21
InChIKey
ZSCDBOWYZJWBIY-UHFFFAOYSA-N
Molecular formula
C20H26N2
Average molar mass
294.4 g/mol
Monoisotopic mass
294.20959884

Overview

Trimipramine is a dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant. It has a role as an antidepressant, a xenobiotic and an environmental contaminant. It is a dibenzoazepine and a tertiary amino compound. It is functionally related to an imipramine.

Names & identifiers

Preferred name
Trimipramine
IUPAC
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amine
English name
Trimeproprimin
Molecular formula
C20H26N2
Molecular weight
294.43

Names & synonyms

trimipramine739-71-9TrimeprimineTrimeproprimineSapilentbeta-MethylimipramineTrimepriminaTrimipraminaTrimipraminum7162 RPIL 6001IL-6001
Show more names
10645RPSurmontylBrn 1321466Trimeproprimin5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N,β-trimethyl-, (-)-5H-Dibenz(B,F)azepine-5-propanamine, 10,11-dihydro-N,N,beta-trimethyl-, (-)- (9ci)5H-Dibenz[b,f]azepine, 5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-, (-)- (8CI)
3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N,2-trimethylpropan-1-amineRP-71625-(3-(Dimethylamino)-2-methylpropyl)-10,11-dihydro-5H-dibenz(b,f)azepine6S082C9NDT5-[3-(dimethylamino)-2-methylpropyl]-10,11-dihydro-5H-dibenz[b,f]azepine7162-RP10,11-dihydro-N,N,beta-trimethyl-5H-dibenz[b,f]azepine-5-propanamine5-(gamma-Dimethylamino-beta-methylpropyl)-10,11-dihydro-5H-dibenzo(b,f)azepine

Database identifiers

CAS

Properties

Computed structural propertiesFilling in

XLogP
5.8
Topological polar surface area
6.5 Ų
Hydrogen bond donors
0
Hydrogen bond acceptors
2
Rotatable bonds
4
Heavy atoms
22
Formal charge
0
Complexity
317

Experimental & physicochemical properties

Drugs · 3 items

DEA NFLIS-Drug Category -> Antidepressants

Pharmaceuticals -> Used in Switzerland

Pharmaceuticals

LogP4.2
Solubility · 2 items

Slightly soluble

2.60e-02 g/L

Human Drugs · 3 items

Antidepressants -> Tricyclic antidepressants (TCA)

Breast Feeding; Lactation; Milk, Human; Antidepressive Agents; Antidepressive Agents, Tricyclic

Pharmaceuticals

Melting Point45 °C
Physical DescriptionSolid
Dissociation Constants · 3 items

9.24

9.24

8.5

Collision Cross Section · 3 items

170.5 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: Antidepressants]

169.17 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (97.8%): Toxic if swallowed [Danger Acute toxicity, oral]

P261, P264, P264+P265, P270, P271, P272, P273, P280, P301+P316, P302+P352, P304+P340, P305+P354+P338, P317, P319, P321, P330, P332+P317, P333+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 46 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information · 2 items

REACH registered substance: Trimipramine (EC: 212-008-3)

Trimipramine: Does not have an individual approval but may be used as a component in a product covered by a group standard. It is not approved for use as a chemical in its own right.

Hazard Classes and CategoriesAcute Tox. 3 (97.8%)

Toxicology

Treatment · 1 item

Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. A minimum of six hours of observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at any time during this period, extended monitoring is required. (L1712)

HepatotoxicityIn clinical trials, liver test abnormalities were uncommon in patients taking trimipramine (

Chemistry & industry

Pharmacology

ATC Code · 2 items

N - Nervous system

QN - Nervous system

Protein Binding93%-96% (to plasma proteins)
Pharmacodynamics · 1 item

Trimipramine is a tricyclic antidepressant. It was thought that tricyclic antidepressants work by inhibiting the re-uptake of the neurotransmitters norepinephrine and serotonin by nerve cells. However, this response occurs immediately, yet mood does not lift for around two weeks. It is now thought that changes occur in receptor sensitivity in the cerebral cortex and hippocampus. The hippocampus is part of the limbic system, a part of the brain involved in emotions. Presynaptic receptors are affected: a1 and b1 receptors are sensitized, a2 receptors are desensitised (leading to increased noradrenaline production). Tricyclics are also known as effective analgesics for different types of pain, especially neuropathic or neuralgic pain. A precise mechanism for their analgesic action is unknown, but it is thought that they modulate anti-pain opioid systems in the CNS via an indirect serotonergic route. They are also effective in migraine prophylaxis, but not in abortion of acute migraine attack. The mechanism of their anti-migraine action is also thought to be serotonergic.

Mechanism of ActionTrimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
Biological Half-Life11-18 hrs
Metabolism/Metabolites · 2 items

Hepatic

Hepatic Half Life: 11-18 hrs

FDA Pharmacological Classification · 6 items

6S082C9NDT

TRIMIPRAMINE

Established Pharmacologic Class [EPC] - Tricyclic Antidepressant

Trimipramine is a Tricyclic Antidepressant.

TRIMIPRAMINE

Tricyclic Antidepressant [EPC]

Related reactions

0 records
New reaction record
No related reactions yet

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
3564-66-7、3564-75-8、739-71-9
PubChem CID
5584
DTXSID
DTXSID8023715
ChEMBL
CHEMBL644
ChEBI
CHEBI:9738
UNII
6S082C9NDT、9K5931C1H5、QJ9MUH57H8
EC Number
212-008-3
Nikkaji
J53.921J、J6.960D、J86.105G

171.2 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Physicochemical properties

Boiling point
411.8 · 411.8±44.0 °C(Predicted)
Density
1.029 · 1.029±0.06 g/cm3(Predicted)
pka
9.38 · 9.38±0.28(Predicted)
FDA UNII
9 K5931C1H5 · 9K5931C1H5
Exposure Routes
Oral. Rapid absorption
Toxicity SummaryTrimipramine's mechanism of action differs from other tricyclic antidepressants. Trimipramine acts by decreasing the reuptake of norepinephrine and serotonin (5-HT).
Signs and Symptoms · 1 item

Side effects include agitation, coma, confusion, convulsions, dilated pupils, disturbed concentration, drowsiness, hallucinations, high fever, irregular heart rate, low body temperature, muscle rigidity, overactive reflexes, severely low blood pressure, stupor, vomiting

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
EPA Human Health Benchmarks for Pharmaceuticals · 6 items

Trimipramine

1.2

4.9

Maintenance therapy is in the range of 50 to 150 mg/day trimipramine maleate.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 50 mg/day, Lowest Therapeutic Dose (LTD): 0.6 mg/kg-day, and Screening Dose: 0.0002 mg/kg-day.

30-Jul-20

MeSH Pharmacological Classification · 2 items

Substances that contain a fused three-ring moiety and are used in the treatment of depression. These drugs block the uptake of norepinephrine and serotonin into axon terminals and may block some subtypes of serotonin, adrenergic, and histamine receptors. However, the mechanism of their antidepressant effects is not clear because the therapeutic effects usually take weeks to develop and may reflect compensatory changes in the central nervous system.

Drugs that block the transport of adrenergic transmitters into axon terminals or into storage vesicles within terminals. The tricyclic antidepressants (ANTIDEPRESSIVE AGENTS, TRICYCLIC) and amphetamines are among the therapeutically important drugs that may act via inhibition of adrenergic transport. Many of these drugs also block transport of serotonin.

Absorption, Distribution and ExcretionRapid absorption
Cellular LocationsMembrane

Uses & manufacturing

Uses · 2 items

Use (kg) in Switzerland (2009): >750

For the treatment of depression and depression accompanied by anxiety, agitation or sleep disturbance

Use Classification · 2 items

Pharmaceuticals

Pharmaceuticals -> Nervous System -> Antidepressants

Additional notes · 1 item

DefinitionChEBI: Trimipramine is a dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant. It has a role as an antidepressant, an environmental contaminant and a xenobiotic. It is a dibenzoazepine and a tertiary amino compound. It is functionally related to an imipramine.